Baxdrostat for Treatment-Resistant Hypertension Reply

被引：0
|
作者：
Freeman, Mason W. [1 ]
Halvorsen, Yuan-Di [1 ]
Brown, Morris J. [2 ]
机构：
[1] CinCor Pharma, Boston, MA USA
[2] Queen Mary Univ London, London, England
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2023年 / 388卷 / 19期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1821 / 1822
页数：2
相关论文
共 50 条
  • [31] Shone syndrome revealed by treatment-resistant hypertension
    Boulouiz, Soumia
    Kossir, Amine
    Mouedder, Fadoua
    Miri, Chaimae
    Ismaili, Nabila
    El Ouafi, Noha
    ANNALS OF MEDICINE AND SURGERY, 2021, 71
  • [32] Prognosis of treatment-resistant hypertension by medication adherence
    Hatta, Tsuguru
    HYPERTENSION RESEARCH, 2025, 48 (03) : 1244 - 1245
  • [33] Venlafaxine and paroxetine in treatment-resistant depression - Reply
    Poirier, MF
    Boyer, P
    BRITISH JOURNAL OF PSYCHIATRY, 1999, 175 : 591 - 591
  • [34] Approval of esketamine for treatment-resistant depression Reply
    Turner, Erick H.
    LANCET PSYCHIATRY, 2020, 7 (03): : 236 - 236
  • [35] LITHIUM ADDITION IN TREATMENT-RESISTANT DEPRESSION - REPLY
    KANTOR, D
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1986, 31 (08): : 795 - 795
  • [36] Treatment-resistant hypertension—a risk factor for ESRD
    Markus P. Schlaich
    Nature Reviews Nephrology, 2014, 10 : 189 - 190
  • [37] Cannabidiol in patients with treatment-resistant epilepsy Reply
    Devinsky, Orrin
    Marsh, Eric
    Friedman, Daniel
    LANCET NEUROLOGY, 2016, 15 (06): : 545 - 546
  • [38] TREATMENT-RESISTANT PATIENTS OR A TREATMENT-RESISTANT SYSTEM
    DIAMOND, RJ
    FACTOR, RM
    HOSPITAL AND COMMUNITY PSYCHIATRY, 1994, 45 (03): : 197 - 197
  • [39] Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension
    Dey, Subo
    Frishman, William H.
    Aronow, Wilbert S.
    CARDIOLOGY IN REVIEW, 2025, 33 (03) : 243 - 245
  • [40] Renal sympathetic nerve ablation for treatment-resistant hypertension
    Krum, Henry
    Schlaich, Markus
    Sobotka, Paul
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (04) : 495 - 503
12345